| Study Forecasts Savings for Marker-Based Cancer Treatment |
| Friday, 16 January 2009 00:00 |
|
Using the anti-EGFR therapy cetuximab (Erbitux) to treat patients with metastatic colorectal cancer who have the normal form of the KRAS gene would save more than $600 million annually, according to study results presented at the Gastrointestinal Cancers Symposium on January 14, 2009. For more information about the study, visit the National Cancer Institute online at www.cancer.gov. |
Follow MPLN
Testing Links
| Test Menu |
| Online Ordering |
| Requisitions and Forms |
| Make a Payment |
Featured Tests
| BRAF Mutations & Melanoma |
| KRAS, BRAF Mutations & CRC |
| Trichomonas Vaginalis on ThinPrep |
Latest News
|
Friday, 06 January 2012
|
|
Wednesday, 04 January 2012
|
|
Wednesday, 04 January 2012
|
|
Monday, 19 December 2011
|
|
Monday, 12 December 2011
|